Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.
about
SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer.Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.Tumor-Specific Systemic Treatment in Advanced Breast Cancer - How Long does it Make Sense?Concise Review: Targeting Cancer Stem Cells Using Immunologic ApproachesRecent advances in systemic therapy for breast cancer: new technologies for a new era.
P2860
Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recent advances in systemic th ...... tive metastatic breast cancer.
@en
Recent advances in systemic th ...... tive metastatic breast cancer.
@nl
type
label
Recent advances in systemic th ...... tive metastatic breast cancer.
@en
Recent advances in systemic th ...... tive metastatic breast cancer.
@nl
prefLabel
Recent advances in systemic th ...... tive metastatic breast cancer.
@en
Recent advances in systemic th ...... tive metastatic breast cancer.
@nl
P2860
P356
P1476
Recent advances in systemic th ...... tive metastatic breast cancer.
@en
P2093
David W Miles
P2860
P2888
P356
10.1186/BCR2237
P577
2009-08-28T00:00:00Z
P5875
P6179
1034711818